Claudia Arce-Salinas

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.5K citations · Full text

Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases

Luis L Rojas-Puentes, Marcelino González-Pinedo, Alejando Crismatt et al. · Radiation Oncology · 2013 · 127 citations · Full text

Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)

Kevin Kalinsky, William E. Barlow, Funda Meric‐Bernstam et al. · Cancer Research · 2021 · 88 citations

Breast Oncology, Cancer Management, Gynecology +18

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E. Geyer, M. Untch, Chiun‐Sheng Huang et al. · New England Journal of Medicine · 2025 · 80 citations · Full text

Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular

Nancy Reynoso‐Noverón, Cynthia Villarreal‐Garza, Enrique Soto‐Pérez‐de‐Celis et al. · Journal of Global Oncology · 2017 · 70 citations · Full text

Mexican Population, Breast Oncology, Cancer Management +16